
|Articles|October 1, 2002
Vaccine could boost survival for node-negative melanoma
Ann Arbor, Mich. - An allogeneic melanoma vaccine - Melacine, made by Corixa Corp. - might provide a survival benefit in node-negative melanoma patients expressing specific HLA class I antigens, according to recent reports.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 2a Evaluation of Dual OX40L/TNFα Antibody Begins in HS
2
Eli Lilly Trial Shows Superior Outcomes With Ixekizumab and Tirzepatide in Patients With PsA and Obesity
3
FDA Feedback Supports BLA Pathway for Sonelokimab in HS
4
Interim Analysis Leads to Early Termination of DUPLEX-AD Study
5


















